-- 日経アジアは水曜日、日本のプライベートクレジットファンドの総資産が2月末時点で7500億円に達し、前年同期の約2.5倍に増加したと報じた。 同紙によると、プライベートクレジットとは、投資ファンドなどのノンバンク機関が、従来の銀行ではなく、主に中堅・中小企業向けに行う融資を指す。 国内投資家がより高いリターンを求めていることがプライベートクレジットファンドの急速な成長を牽引している一方、海外投資家は直接融資への懸念から撤退の動きを見せていると、同紙は伝えている。 日経アジアは水曜日、クイック・アセット・マネジメント・リサーチセンターのデータを引用し、日本のプライベートクレジット分野の公募投資信託の資産は5年前には約30億円に過ぎなかったと報じた。 （マーケットチャッターニュースは、世界中の市場関係者との会話に基づいています。この情報は信頼できる情報源に基づいていると考えられますが、噂や憶測が含まれる可能性があります。正確性は保証されません。）
Related Articles
Asia
National Australia Bank Shares Down After Resolution of Union Court Proceedings
National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."
$ASX:NAB
Asia
Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant
Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.
$ASX:CUV
Asia
XRF Scientific Completes Acquisition of Combustion Gas Analysis Business
XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.
$ASX:XRF